FOR IMMEDIATE RELEASE

March 8, 2018

MEDIA CONTACT:
Kathy Markham
Marketing Manager
Phone: 253.274.7165
Email: KMarkham@Unigen.net

New AmLexin™ data validates increased exercise recovery and reduced DOMS

Unigen’s next generation joint protection product AmLexin™ has been clinically proven to aggressively support exercise recovery and within 1 to 3 days reduce delayed onset of muscular soreness post-exercise in healthy adults.

This is the second clinical trial of AmLexin™ to demonstrate its health benefits in relieving discomfort, stiffness and improving mobility in healthy adults. In the first clinical trial, AmLexin™ showed statistically significant reduction of a urinary biomarker for cartilage breakdown – uCTX-II. AmLexin™ was proven to protect joint cartilage from damage, reducing the amount of glycosaminoglycan released by articular cartilage and to be an effective quencher of super oxide anion, a free radical generated by tissue wear and tear. Supporting clinical data has been published in a peer reviewed journal, further validating the previously published multiple pre-clinical efficacy and mechanism of action articles.

The recently completed clinical study examined the effects of AmLexin™ (combination of Acacia catechu heartwood extract and Morus alba root bark extract) on delayed onset muscular soreness, exercise recovery and redox balance in healthy runners assessed in a single center, double blind placebo controlled clinical trial.

Twenty-six subjects completed the 9-week supplementation trial. Subjects were supplemented with 400 mg of AmLexin™/day or a look-alike placebo during an 8-week running training program and for one-week following a 13.1-mile half-marathon run. Results showed the AmLexin™ groups to experience significantly lower levels of post-exercise muscle soreness on days 1, 2, and 3 following the half-marathon compared to the placebo group. The AmLexin™ group showed lower levels of post-exercise discomfort measures following extraneous exercise compared to the placebo group. These results demonstrate the rapid-acting benefits of AmLexin™ on exercise recovery of healthy adults within 1 to 6 days post-exercise.

“AmLexin™ is the second generation of joint care ingredient launched by Unigen following our successful joint care ingredient Univestin® which is moving into the 15th year of global usage,” stated Regan Miles, Unigen’s President and Chief Executive Officer. “Unigen is committed to substantiating AmLexin™ with solid science and defining it as one of the most extensively studied joint care ingredients similar to its counterpart Univestin®.” Miles emphasized that Unigen’s commitment includes peer-reviewed publications, noted for high quality clinical trials,
combined with the numerous pre-clinical articles on MOA, efficacy and safety studies. “Effect of AmLexin™ (Acacia catechu & Morus alba) on Redox Balance and Subjective Pain in Healthy Runners” has been accepted for presentation at Experimental Biology 2018 in San Diego, California April 21-25.

###

**About Unigen**

Unigen discovers, develops and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through our high throughput screening PhytoLogix™ approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety and efficacy are documented with extensive preclinical *in vitro* and *in vivo* testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories, and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution and marketing of end-products in each of Unigen’s target markets. [www.Unigen.net](http://www.Unigen.net)